Sight Sciences ASCRS 2024 TearCare Update

This year at ASCRS Sight Sciences announced the results of phase 2 of the Sahara Trial. In phase 2 they found that a single TearCare procedure improved signs and symptoms for patients beyond what was achieved with six months of Restasis. Data like this suggests that Tear Care can be a primary treatment for #dryeye patients. Thank you Matt Gibson for talking with iDocSocial References: Ayres BD, Bloomenstein MR, Loh J, Chester T, Saenz B, Echegoyen J, Kannarr SR, Perez VL, Rodriguez TC, Dickerson JE Jr. A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA). Clin Ophthalmol. 2023 Dec 18;17:3925-3940. doi: 10.2147/OPTH.S442971. PMID: 38143559; PMCID: PMC10741761. Ayres, B. Tear Break-up, Meibomian Gland, and Dry Eye Symptom Improvement for Cyclosporine-Treated Patients after Localized Heat Therapy Treatment (SAHARA Cross-Over/phase 2) – oral presentation. Presented at: American Society of Cataract and Refractive Surgery meeting; April 5-8, 2024; Boston. #tearcare #ocularsurfacedisease #eyecare